One To Watch

Nuage Tx was founded in Barcelona in 2021 by Dr. Xavier Salvatella and Dr. Mateusz Biesaga from the Institute for Research in Biomedicine (IRB Barcelona), together with Dr. Denes Hnisz from the Max Planck Institute in Berlin.

The company, currently led by Stuart Hughes, is developing new drugs targeting pharmacological proteins that, until now, have been considered undruggable by the pharmaceutical industry due to their lack of defined structure—commonly known as Intrinsically Disordered Proteins (IDPs). Nuage Tx aims to shift the paradigm in how IDPs are approached, transforming them from “undruggable” to “druggable” targets.

Nuage closed a 12 million euros ($13.4 million) seed financing in 2023 to support the development of its lead program and validate its pioneering drug discovery platform. The financing round was led by Sofinnova Partners, a leading European venture capital firm in life sciences, and Asabys, a venture capital firm based in Barcelona and specialised in the healthcare sector, with the participation of Innvierte, an investment program of CDTI Innovación, and BStartup.